drugset / Trial / NCT00917826
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.
Timeline
- Start
- 2008-09
- Primary completion
- 2009-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arginine Butyrate | Small molecule | 1000 mg/kg | Intravenous |
| Subject | Ganciclovir | Small molecule | 5 mg/kg | Intravenous |
| Subject | Valganciclovir | Small molecule | 900 mg | Oral |